Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

NCT04480827 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Aramchol free acid tablet 600mg, single dose
DRUG: Aramchol free acid tablet 300mg, bid

Sponsor

Galmed Research and Development, Ltd.